Skip to main content
Three women sewing

How do dose reductions affect overall survival with KISQALI?

Across the 3 trials, overall survival (OS) was studied in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who received one or more dose reductions of KISQALI® (ribociclib). Post hoc analyses of data from the 3 phase III MONALEESA clinical trials assessed OS in patients treated with KISQALI, in combination with an aromatase inhibitor (AI) or fulvestrant, who required dose reduction. Efficacy in the placebo comparator arms was not assessed. Review the data below to learn about KISQALI efficacy data in patients requiring dose reductions.1-5
KISQALI Treatment Guide

KISQALI Treatment Guide

A comprehensive guide to treatment with KISQALI + AI that includes dedicated sections to support you in treating your patients with early (stage II or III at high risk of recurrence) or metastatic HR+/HER2- breast cancer.
Download
References: 1. Data on file. ML2 OS by dose reduction. Novartis Pharmaceuticals Corp; 2021. 2. Data on file. CLEE011A2301 additional analysis. Novartis Pharmaceuticals Corp; 2021. 3. Data on file. OS by dose reduction poster. Novartis Pharmaceuticals Corp; 2020. 4. Data on file. CLEE011F2301 additional analysis. Novartis Pharmaceuticals Corp; 2020. 5. Data on file. CLEE011E2301 additional analysis. Novartis Pharmaceuticals Corp; 2020. 6. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 7. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663 8. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472. doi:10.1200/JCO.2018.78.9909 9. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149 10. Neven P, Fasching PA, Chia S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023;25(1):103. doi:10.1186/s13058-023-01701-9 11. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomized phase 3 trial. Lancet Oncol. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4 12. Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316. doi:10.1056/NEJMoa1903765 13. Lu Y-S, Im S-A, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851-859. doi:10.1158/1078-0432.CCR-21-3032 14. Data on file. CLEE011E2301. Novartis Pharmaceuticals Corp; 2020.